| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Sabina A Murphy | Q114308442 |
| Eugene Braunwald | Q322114 | ||
| P2093 | author name string | M Cohen | |
| E M Antman | |||
| C McCabe | |||
| S G Goodman | |||
| TIMI 11B and ESSENCE Investigators | |||
| P433 | issue | 4 | |
| P921 | main subject | heparin | Q190016 |
| P304 | page(s) | 308-314 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. | |
| P478 | volume | 23 |
| Q35546171 | A Novel Risk Stratification Model for Patients with Non-ST Elevation Myocardial Infarction in the Korea Acute Myocardial Infarction Registry (KAMIR): Limitation of the TIMI Risk Scoring System |
| Q73245550 | Acute Myocardial Infarction: Antithrombotic Therapy |
| Q34767433 | Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update |
| Q42611184 | Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study |
| Q44492670 | Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. |
| Q28165924 | Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes |
| Q46723049 | Dysphagia after taking an acetaminophen-tablet during oral anticoagulation |
| Q44739387 | Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction |
| Q28301431 | Enoxaparin in acute coronary syndromes |
| Q28239975 | Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology |
| Q38362096 | Heparin and heparan sulfate disaccharides bind to the exchanger inhibitor peptide region of Na+/Ca2+ exchanger and reduce the cytosolic calcium of smooth muscle cell lines. Requirement of C4-C5 unsaturation and 1--> 4 glycosidic linkage for activity |
| Q51065519 | Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. |
| Q84395828 | Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome |
| Q28193196 | Low molecular weight heparins and glycoprotein IIb/IIIa antagonists |
| Q47446286 | Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on |
| Q44557763 | Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events |
| Q46375283 | TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. |
| Q38015757 | Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents |
| Q73047232 | [Present and future of antithrombotic therapy in acute coronary syndromes] |
| Q82718146 | [Stocked medications in emergency physician-based medical services in Germany. Reality and requirements according to guidelines] |
Search more.